EDAP Stock Overview
EDAP TMS S.A., together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally invasive medical devices for the treatment of urological diseases in Asia, France, the United States, and internationally.
No risks detected for EDAP from our risk checks.
EDAP TMS Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$8.12|
|52 Week High||US$8.99|
|52 Week Low||US$5.00|
|1 Month Change||-5.53%|
|3 Month Change||19.34%|
|1 Year Change||25.81%|
|3 Year Change||85.70%|
|5 Year Change||166.07%|
|Change since IPO||-4.53%|
Recent News & Updates
EDAP TMS stock falls 7% aftermarket on proposed ADS offering
EDAP TMS (NASDAQ:EDAP) stock fell ~7% postmarket after the company said it commenced a public offering of its American depositary shares, each representing one ordinary share. There can be no assurance as to whether or when the proposed offering may be completed or the actual size or terms.
|EDAP||US Medical Equipment||US Market|
Return vs Industry: EDAP exceeded the US Medical Equipment industry which returned -31.4% over the past year.
Return vs Market: EDAP exceeded the US Market which returned -22.1% over the past year.
|EDAP Average Weekly Movement||8.3%|
|Medical Equipment Industry Average Movement||8.6%|
|Market Average Movement||6.9%|
|10% most volatile stocks in US Market||15.8%|
|10% least volatile stocks in US Market||2.8%|
Stable Share Price: EDAP is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 8% a week.
Volatility Over Time: EDAP's weekly volatility (8%) has been stable over the past year.
About the Company
EDAP TMS S.A., together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally invasive medical devices for the treatment of urological diseases in Asia, France, the United States, and internationally. It operates in three segments: High Intensity Focused Ultrasound (HIFU), Extracorporeal ShockWave Lithotripsy (ESWL), and Distribution Services (DIST). The HIFU segment develops, manufactures, and markets medical devices based on HIFU technology for the minimally invasive treatment of urological and other clinical indications.
EDAP TMS Fundamentals Summary
|EDAP fundamental statistics|
Is EDAP overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|EDAP income statement (TTM)|
|Cost of Revenue||€28.77m|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||0.076|
|Net Profit Margin||5.01%|
How did EDAP perform over the long term?See historical performance and comparison
Is EDAP undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 1/6
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for EDAP?
Other financial metrics that can be useful for relative valuation.
|What is EDAP's n/a Ratio?|
Price to Earnings Ratio vs Peers
How does EDAP's PE Ratio compare to its peers?
|EDAP PE Ratio vs Peers|
|Company||PE||Estimated Growth||Market Cap|
SRTS Sensus Healthcare
SMLR Semler Scientific
RBOT Vicarious Surgical
EDAP EDAP TMS
Price-To-Earnings vs Peers: EDAP is expensive based on its Price-To-Earnings Ratio (111.2x) compared to the peer average (21x).
Price to Earnings Ratio vs Industry
How does EDAP's PE Ratio compare vs other companies in the US Medical Equipment Industry?
Price-To-Earnings vs Industry: EDAP is expensive based on its Price-To-Earnings Ratio (111.2x) compared to the US Medical Equipment industry average (31.9x)
Price to Earnings Ratio vs Fair Ratio
What is EDAP's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PE Ratio||111.2x|
|Fair PE Ratio||57.9x|
Price-To-Earnings vs Fair Ratio: EDAP is expensive based on its Price-To-Earnings Ratio (111.2x) compared to the estimated Fair Price-To-Earnings Ratio (57.9x).
Share Price vs Fair Value
What is the Fair Price of EDAP when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: EDAP ($8.12) is trading above our estimate of fair value ($2.18)
Significantly Below Fair Value: EDAP is trading above our estimate of fair value.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.
Discover undervalued companies
How is EDAP TMS forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?
Future Growth Score4/6
Future Growth Score 4/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: EDAP's forecast earnings growth (55.4% per year) is above the savings rate (1.9%).
Earnings vs Market: EDAP's earnings (55.4% per year) are forecast to grow faster than the US market (14.8% per year).
High Growth Earnings: EDAP's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: EDAP's revenue (15.3% per year) is forecast to grow faster than the US market (7.6% per year).
High Growth Revenue: EDAP's revenue (15.3% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if EDAP's Return on Equity is forecast to be high in 3 years time
Discover growth companies
How has EDAP TMS performed over the past 5 years?
Past Performance Score5/6
Past Performance Score 5/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: EDAP has high quality earnings.
Growing Profit Margin: EDAP's current net profit margins (5%) are higher than last year (0.3%).
Past Earnings Growth Analysis
Earnings Trend: EDAP has become profitable over the past 5 years, growing earnings by 26.7% per year.
Accelerating Growth: EDAP's earnings growth over the past year (1864.3%) exceeds its 5-year average (26.7% per year).
Earnings vs Industry: EDAP earnings growth over the past year (1864.3%) exceeded the Medical Equipment industry 0.6%.
Return on Equity
High ROE: EDAP's Return on Equity (4.8%) is considered low.
Discover strong past performing companies
How is EDAP TMS's financial position?
Financial Health Score4/6
Financial Health Score 4/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: EDAP's short term assets (€70.9M) exceed its short term liabilities (€19.8M).
Long Term Liabilities: EDAP's short term assets (€70.9M) exceed its long term liabilities (€9.2M).
Debt to Equity History and Analysis
Debt Level: EDAP has more cash than its total debt.
Reducing Debt: EDAP's debt to equity ratio has increased from 6.8% to 17% over the past 5 years.
Debt Coverage: EDAP's debt is well covered by operating cash flow (55.8%).
Interest Coverage: Insufficient data to determine if EDAP's interest payments on its debt are well covered by EBIT.
Discover healthy companies
What is EDAP TMS current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Cash Flow Coverage
Dividend Yield vs Market
|EDAP TMS Dividend Yield vs Market|
|Company (EDAP TMS)||n/a|
|Market Bottom 25% (US)||1.6%|
|Market Top 25% (US)||4.6%|
|Industry Average (Medical Equipment)||1.9%|
|Analyst forecast in 3 Years (EDAP TMS)||n/a|
Notable Dividend: Unable to evaluate EDAP's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate EDAP's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if EDAP's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if EDAP's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as EDAP has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Marc Oczachowski (52 yo)
Mr. Marc Oczachowski has been Chief Executive Officer of EDAP TMS SA since March 31, 2007 and its Executive Director since July 1, 2017. Mr. Oczachowski serves as Executive Chairman of the Board at EDAP TM...
Experienced Management: EDAP's management team is considered experienced (4.8 years average tenure).
Experienced Board: EDAP's board of directors are seasoned and experienced ( 13.2 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
|Owner Type||Number of Shares||Ownership Percentage|
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
|Ownership||Name||Shares||Current Value||Change %||Portfolio %|
EDAP TMS S.A.'s employee growth, exchange listings and data sources
- Name: EDAP TMS S.A.
- Ticker: EDAP
- Exchange: NasdaqGM
- Founded: 1979
- Industry: Health Care Equipment
- Sector: Healthcare
- Implied Market Cap: US$271.578m
- Shares outstanding: 33.47m
- Website: https://www.edap-tms.com
Number of Employees
- EDAP TMS S.A.
- Parc dActivites la Poudrette-Lamartine
- 4/6, rue du DauphinE
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|EDAP||NasdaqGM (Nasdaq Global Market)||Yes||ADS EACH REPR 1 ORD SHARE FRF0.8||US||USD||Aug 1997|
|EDA||DB (Deutsche Boerse AG)||Yes||ADS EACH REPR 1 ORD SHARE FRF0.8||DE||EUR||Aug 1997|
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/09/28 00:00|
|End of Day Share Price||2022/09/28 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.